SSC 2026 Guidelines now available — 129 adult & 61 pediatric recommendations View guidelines →
Evidence-based guideline for risk assessment, prophylaxis, diagnosis, and treatment of venous thromboembolism in cancer patients, including catheter-related thrombosis.
Comprehensive management of central venous access device-related thrombosis including diagnosis, treatment, catheter management decisions, upper extremity DVT, patient education, monitoring, and follow-up.
Management of cancer-associated VTE in special populations including brain tumors, thrombocytopenia, renal impairment, GI/GU cancers, recurrent VTE on anticoagulation, incidental and subsegmental PE, and IVC filter indications.
Complete treatment protocols for cancer-associated VTE including LMWH dosing, DOAC regimens (rivaroxaban, edoxaban, apixaban), warfarin considerations, duration of anticoagulation, and landmark trial data from SELECT-D, HOKUSAI-VTE Cancer, ADAM-VTE, and CARAVAGGIO.
Evidence-based recommendations for VTE prophylaxis in ambulatory, hospitalized, and surgical cancer patients, including CVAD-related thrombosis prevention, with complete dosing tables and key trial data.
Pathophysiology of cancer-associated thrombosis, Virchow's triad in malignancy, and validated VTE risk assessment models including the Khorana score, Vienna CATS score, PROTECHT score, and ONKOTEV score with complete scoring tables.
Complete clinical guide to catheter-associated thrombosis: PICC-associated UEDVT (incidence, risk factors, diagnosis), fibrin sheath, treatment options (anticoagulation, catheter removal decision), and prevention strategies.